Breaking News
Investing Pro 0
🚨 Our Pro Data Reveals the True Winner of Earnings Season Access Data

Novartis Accused Of Threatening Docs Over Cheaper Drug

Stock Markets Apr 02, 2015 10:45AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Karen Bleier/AFP/Getty Images. Drugmaker Novartis may have blocked doctors' access to an alternative drug to treat a form of the eye condition macular degeneration, an investigation by the British Medical Journal suggests.

By Elizabeth Whitman -

Drugmaker Novartis is under scrutiny for allegedly blocking British doctors' access to the drug Avastin, a cheaper alternative to one that it sells, Lucentis, as doctors and academics have faced "threats and intimidation" when carrying out clinical trials on Avastin, an investigation by the British Medical Journal claims. Both drugs are used to treat an eye condition that is a leading cause of blindness among older British patients.

The journal said it had uncovered a campaign by drugmakers to "undermine and divert attention" from these trials, which suggested that Avastin was just as safe and effective as Lucentis in treating the eye condition. Those efforts included emails from clinicians that had links to Novartis urging some to pull out of one drug trial, as well as attempts by the company to "derail" another trial, according to the journal.

Lucentis costs $1,950 per dose, while Avastin costs about $50 per dose, the journal said in a press release. If doctors were allowed to use Avastin to treat the eye condition, the U.K. could save more than $150 million a year, it added. Avastin is currently sold as a cancer drug, and though it is not licensed to treat the eye condition, wet age-related macular degeneration, some doctors prescribe it nonetheless, given trials indicate that the drug can be effective against the condition, BBC reported.

Novartis has denied allegations that the company was, in the words of Dr. Fiona Godlee, chief editor of the medical journal, "scaring doctors from using cheap and effective medicines." A spokesman for the company told the BBC that it was "closely reviewing the content of the article" in the journal.

Both Lucentis and Avastin are owned by drug company Roche, but Novartis markets Lucentis in the U.K. The Royal College of Opthamology has called for Avastin to be approved to treat the eye condition in Britain. Elsewhere in the world, Avastin is widely used in opthamology, and the World Health Organization supports its use for such purposes.

Novartis Accused Of Threatening Docs Over Cheaper Drug
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email